Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

Manish Sharma, Farhad Ravandi, Ulas Darda Bayraktar, Alexandre Chiattone, Qaiser Bashir, Sergio Giralt, Julianne Chen, Muzaffar Qazilbash, Partow Kebriaei, Marina Konopleva, Michael Andreeff, Jorge Cortes, Deborah McCue, Hagop Kantarjian, Richard E. Champlin, Marcos De Lima

Research output: Contribution to journalArticle

Abstract

Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT). Sorafenib, an inhibitor of multiple kinases including FLT3, has shown promising activity in FLT3-ITD-positive AML. We treated 16 patients with FLT3-ITD-positive AML who relapsed after HSCT with sorafenib alone (n = 8) or in combination with cytotoxic chemotherapy (n = 8). The number of circulating blasts decreased in 80% of cases, but none of the patients achieved complete remission (CR); 3 achieved partial remission. Two patients were bridged to a second transplantation but both relapsed within 3 months of the transplantation. Median overall survival (OS) was 83 days, with none surviving more than a year. Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Preventive strategies after HSCT may be more suitable for these high-risk patients.

Original languageEnglish (US)
Pages (from-to)1874-1877
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number12
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Acute Myeloid Leukemia
Hematopoietic Stem Cell Transplantation
Transplantation
Therapeutics
Receptor Protein-Tyrosine Kinases
Phosphotransferases
sorafenib
Drug Therapy
Mutation
Survival
Genes

Keywords

  • Acute myeloid leukemia
  • FLT3
  • Sorafenib
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. / Sharma, Manish; Ravandi, Farhad; Bayraktar, Ulas Darda; Chiattone, Alexandre; Bashir, Qaiser; Giralt, Sergio; Chen, Julianne; Qazilbash, Muzaffar; Kebriaei, Partow; Konopleva, Marina; Andreeff, Michael; Cortes, Jorge; McCue, Deborah; Kantarjian, Hagop; Champlin, Richard E.; De Lima, Marcos.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 12, 01.12.2011, p. 1874-1877.

Research output: Contribution to journalArticle

Sharma, M, Ravandi, F, Bayraktar, UD, Chiattone, A, Bashir, Q, Giralt, S, Chen, J, Qazilbash, M, Kebriaei, P, Konopleva, M, Andreeff, M, Cortes, J, McCue, D, Kantarjian, H, Champlin, RE & De Lima, M 2011, 'Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib', Biology of Blood and Marrow Transplantation, vol. 17, no. 12, pp. 1874-1877. https://doi.org/10.1016/j.bbmt.2011.07.011
Sharma, Manish ; Ravandi, Farhad ; Bayraktar, Ulas Darda ; Chiattone, Alexandre ; Bashir, Qaiser ; Giralt, Sergio ; Chen, Julianne ; Qazilbash, Muzaffar ; Kebriaei, Partow ; Konopleva, Marina ; Andreeff, Michael ; Cortes, Jorge ; McCue, Deborah ; Kantarjian, Hagop ; Champlin, Richard E. ; De Lima, Marcos. / Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 12. pp. 1874-1877.
@article{764356b1b23b47be8346b98671b5950a,
title = "Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib",
abstract = "Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT). Sorafenib, an inhibitor of multiple kinases including FLT3, has shown promising activity in FLT3-ITD-positive AML. We treated 16 patients with FLT3-ITD-positive AML who relapsed after HSCT with sorafenib alone (n = 8) or in combination with cytotoxic chemotherapy (n = 8). The number of circulating blasts decreased in 80{\%} of cases, but none of the patients achieved complete remission (CR); 3 achieved partial remission. Two patients were bridged to a second transplantation but both relapsed within 3 months of the transplantation. Median overall survival (OS) was 83 days, with none surviving more than a year. Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Preventive strategies after HSCT may be more suitable for these high-risk patients.",
keywords = "Acute myeloid leukemia, FLT3, Sorafenib, Stem cell transplantation",
author = "Manish Sharma and Farhad Ravandi and Bayraktar, {Ulas Darda} and Alexandre Chiattone and Qaiser Bashir and Sergio Giralt and Julianne Chen and Muzaffar Qazilbash and Partow Kebriaei and Marina Konopleva and Michael Andreeff and Jorge Cortes and Deborah McCue and Hagop Kantarjian and Champlin, {Richard E.} and {De Lima}, Marcos",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.bbmt.2011.07.011",
language = "English (US)",
volume = "17",
pages = "1874--1877",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

AU - Sharma, Manish

AU - Ravandi, Farhad

AU - Bayraktar, Ulas Darda

AU - Chiattone, Alexandre

AU - Bashir, Qaiser

AU - Giralt, Sergio

AU - Chen, Julianne

AU - Qazilbash, Muzaffar

AU - Kebriaei, Partow

AU - Konopleva, Marina

AU - Andreeff, Michael

AU - Cortes, Jorge

AU - McCue, Deborah

AU - Kantarjian, Hagop

AU - Champlin, Richard E.

AU - De Lima, Marcos

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT). Sorafenib, an inhibitor of multiple kinases including FLT3, has shown promising activity in FLT3-ITD-positive AML. We treated 16 patients with FLT3-ITD-positive AML who relapsed after HSCT with sorafenib alone (n = 8) or in combination with cytotoxic chemotherapy (n = 8). The number of circulating blasts decreased in 80% of cases, but none of the patients achieved complete remission (CR); 3 achieved partial remission. Two patients were bridged to a second transplantation but both relapsed within 3 months of the transplantation. Median overall survival (OS) was 83 days, with none surviving more than a year. Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Preventive strategies after HSCT may be more suitable for these high-risk patients.

AB - Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT). Sorafenib, an inhibitor of multiple kinases including FLT3, has shown promising activity in FLT3-ITD-positive AML. We treated 16 patients with FLT3-ITD-positive AML who relapsed after HSCT with sorafenib alone (n = 8) or in combination with cytotoxic chemotherapy (n = 8). The number of circulating blasts decreased in 80% of cases, but none of the patients achieved complete remission (CR); 3 achieved partial remission. Two patients were bridged to a second transplantation but both relapsed within 3 months of the transplantation. Median overall survival (OS) was 83 days, with none surviving more than a year. Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Preventive strategies after HSCT may be more suitable for these high-risk patients.

KW - Acute myeloid leukemia

KW - FLT3

KW - Sorafenib

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=80054771760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054771760&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.07.011

DO - 10.1016/j.bbmt.2011.07.011

M3 - Article

C2 - 21767516

AN - SCOPUS:80054771760

VL - 17

SP - 1874

EP - 1877

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -